Assessment of the impact of pathogen reduction technologies on the neutralizing activity of COVID-19 convalescent plasma.

COVID-19 convalescent plasma (CCP) could improve the clinical outcome of COVID-19 patients when high-titer CCP is administered in early stages of disease. However, CCP donors have a risk profile like first-time donors, pathogen reduction treatment (PRT) may mitigate such risk but should not impact CCP quality. The current study aims to assess the impact of PRT-technologies available in Saudi Arabia on the neutralizing activity of CCP.

https://www.trasci.com/article/S1473-0502(23)00056-3/fulltext?rss=yes

Source: Transfusion and Apheresis Science - March 3, 2023 Category: Hematology Authors: Salwa Hindawi, Tarek Elgemmezi, Sherif El-Kafrawi, Hani Samadani, Myasin Tilmisani, Omar Assiri, Mohammad Raml, Esam Azhar, Maha Badawi Source Type: research